news
KRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
List view / Grid view
Memorial Sloan Kettering Cancer Center
news
Elucidating MDLC’s molecular features
The study’s results indicate that spatial sequencing of mixed-type breast cancers could inform personalised treatment.
news
Predicting pancreatic cancer metastasis
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
news
Spectra: new insights to improve immunotherapy treatments
New open-source computational method called Spectra improves analysis of single-cell transcriptomic data.
news
New prostate cancer subtype may illuminate treatment strategy
Researchers have identified a previously unrecognised form of hormone therapy-resistant prostate cancer.
article
A novel target revealed for myelodysplastic syndrome
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
news
New study shows insight into how cells maintain their identity
A new study shows the ways in which epigenetic mechanisms control the activity of genes and may have an impact on the future treatment of certain cancers.
news
Researchers develop a remote-controlled cancer immunotherapy system
Researchers have developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognise and kill cancer cells.
news
Theranostic system can eliminate colorectal cancer
Three-step pretargeted radioimmunotherapy offers safe and effective treatment for colorectal cancer...
news
Aprea Therapeutics to collaborate with Memorial Sloan Kettering cancer center
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
news
Tri-I TDI expands focus to include antibody drug discovery
17 June 2016 | By Victoria White, Digital Content Producer
Tri-I TDI will extend its current relationship with Takeda from the realm of small molecule discovery into the new research area of antibody drug discovery...
news
Stem cell approach offers a first step in treating hypopituitarism
14 June 2016 | By Victoria White, Digital Content Producer
Stem cell generated functional pituitary tissue promoted normal hormone release when transplanted into rats with hypopituitarism...
news
Novel radioimmunotherapy results in complete remission in preclinical colorectal cancer study
13 June 2016 | By Victoria White, Digital Content Producer
Researchers have unveiled a novel radioimmunotherapy that resulted in complete remission of colorectal cancer in mouse models...